



SoMex Research & Health Organization
www.somexresearch.com



BEST CLINICAL ONCOLOGY SYMPOSIUM 2020

Recent Advances in the Management of Lung Cancer

Thursday, 11th June 2020
06:00 pm to 09:00 pm



Dr Naresh Somani
Senior Consultant,
Medical Oncology
BMCHRC,
Jaipur



Dr Pawan Aggarwal
Senior Consultant,
Medical Oncology
BMCHRC,
Jaipur



Dr Sandeep Jasuja
Medical Superintendent State
Cancer Institute
HOD, Dept. of Medical Oncology
SMS Medical College & Hospital, Jaipur

 oncoupdate2020@gmail.com

SPEAKERS



Prof (Dr) Chandra Belani
Professor, Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute,
Pennsylvania



Dr Ajit Venniyoor
Senior Consultant (Medical Oncology)
National Oncology Centre
The Royal Hospital,
Muscat, Sultanate of Oman



Dr Kumar Prabhash
Prof. & Head- Department
of Medical Oncology,
Tata Memorial Hospital Parel,
Mumbai




Dr Satya Dattatreya
Sr. Consultant Medical Oncologist,
Omega Hospitals,
Bhailal Amin General Hospital,
Hyderabad



Dr Ullas Batra
Senior Consultant, Medical Oncology
Chief of Thoracic Medical Services
Rajiv Gandhi Cancer Institute and Research Centre,
Delhi

SPEAKERS



Dr Anjana Joel

Assistant Professor in Medical Oncology
Christian Medical College and Hospital,
Penn State Cancer Institute,
Vellore

Dr Bivas Biswas
Consultant Department
of Medical Oncology
Tata Medical Center,
Kolkata



Dr Sewanti Limaye

Consultant, Medical Oncologist
Director Clinical and Translational Oncology Research
Kokilaben Dhirubhai Ambani Hospital,
Mumbai

Dr Vijay Agarwal
Lead and Senior Consultant - Medical Oncology and Hematology
Chief of Thoracic Medical Services
Aster CMI Hospital
Bengaluru, Karnataka



Dr Vikas Talreja

Consultant -Specialist
Dept of Medical Oncology & Hematology
Safdarjung Hospital & Vardhman Mahavir Medical College
New Delhi

WEBINAR AGENDA

Time	Topics	Speakers
6.00pm-6.30pm	Industry Sponsored Symposium Novartis	
6.30pm-7.00pm	Industry Sponsored Symposium Pfizer	
	Plenary Session 1	
	Chairpersons: Dr Ajit Venniyoor- Muscat, Dr Chirag Desai- Ahmedabad, Dr DP Singh- Jaipur	
7.00pm-7.20pm	Locally Advanced NSCLC & Immune Check Point Inhibitor;How best to select patient	Dr Chandra Belani, USA
	Plenary Session 2	
	Chairpersons: Dr K Pavithran- Kochi, Dr D Loknatha, Bengaluru	
7.20pm - 7.40pm	Immunotherapy in driver mutation positive NSCLC "When to use When not to use and How to use"	Dr Kumar Prabhash, Mumbai
	Key Note Address	
	Chairperson : Dr Vanita Noronha- Mumbai, Dr R P Baral- Nepal, Dr Jitendra Kumar Pehalajani-Jaipur	
7.40pm-8.00pm	Discovery Of Newer Actionable targets in Lung Cancer : A Keen Look at BRAF and other Mutations	Dr Satya Dattatreya, Hyderabad
	Highlight Sessions	
	Chairperson : Dr. Navneet Singh- Chandigarh, Dr Lovenish Goyal- Hisar, Dr Sameer Khatri-Delhi	
8.00pm-8.07pm	Keynote :604 Pembrolizumab(Pembro)or Placebo plus Etoposide and Platinum (EP) as First- Line Therapy For Extensive - stage (ES) Small Cell Lung Cancer(SCLC)	Dr Anjana Joel, Vellore

WEBINAR AGENDA

Time	Topics	Speakers
8.07pm-8.14pm	Randomized phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide(CE) alone or in combination with Nivolumab as frontline therapy for Extensive-stage Small cell Lung Cancer (ES-SCLC) ECOG-ECRIN EA5161	Dr Vikas Talreja, Delhi
8.14pm-8.21pm	Durvalumab ± tremelimumab+Platinum-Etoposide in First Line Extensive stage SCLC(ES-SCLC) Updated Results from the Phase III CASPIAN Study	Dr Bivas Biswas, Kolkata
8.21pm - 8.41pm	Panel Discussion(Based on the HighLight Session) Panelist : Dr Vijay Patil- Mumbai, Dr Rajat Saha- Delhi, Dr Aditya Murli- Bangalore, Dr Rekha Bansal- Hyderabad, Dr Divesh Goyal- Jaipur, Dr Sachin Jain- Udaipur Chairpersons : Dr Surender Beniwal- Bikaner, Dr Hemant Dadhich- Kota, Dr Ghanshyam Biswas- Cuttack	Moderator- Dr Ullas Batra, Delhi
8.41pm- 8.48pm	First Line Tyrosine Kinsase Inhibitor with or without upfront Local Radiation therapy in patients with EGFRm Oligometastatic Non-Small cell Lung Cancer Interim Results of a Randomized Phase III open label clinical trial (SINDAS) (NCT02893332)	Dr Vijay Agarwal , Bengaluru
8.48pm - 8.55pm	CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer	Dr Sewanti Limaye, Mumbai
8.55pm - 9.00pm	Concluding Remarks & Words of wisdom	Dr Ajit Venniyoor, Muscat